CD274 and non-small cell lung carcinoma: Currently, Pembrolizumab, an anti-PD-1 agent, is approved for use as both first-line and second-line treatment in advanced NSCLC patients whose tumors show PD-L1 expression in immunohistochemical analysis [92].